REGULATORY

Japan Approves Slew of Generics towards June Listing; Samsca, Xarelto AGs Too

February 16, 2022

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Japan’s Ministry of Health, Labor and Welfare (MHLW) approved generics for 28 APIs (127 products) on February 15 towards the next biannual listing in June, giving the nod to authorized versions of multiple major brands such as Samsca (tolvaptan) and…

To read the full story

Feburic, Samsca, and More Face First Generics in June Listing, No Xarelto/Eylea AGs
June 16, 2022

REGULATORY

Japan Approves AbbVie’s Aquipta, Novo’s IcoSema, Pfizer’s Tukysa, and More
February 20, 2026
Takaichi Urges Public-Private Investment Push in Drug Discovery
February 20, 2026
Two iPSC-Derived Products Now in Line for Conditional Approval
February 20, 2026
PM Takaichi Keeps Cabinet Intact after Lower House Vote
February 18, 2026
LDP Returnees Set Sights on Social Security, Drug Policy as Special Diet Opens
February 18, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Hisamitsu’s MBO: Is Shareholder Accountability Trust-Building or a Shackle?

By Hayate Horiguchi

Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…

COLUMN

AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential

By Philip Carrigan

The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…